Effects of gender affirming hormone therapy on body mass index in transgender individuals: A longitudinal cohort study

Pichatarn Suppakitjanusanta, Yuhan Ji, Mary O. Stevenson, Panicha Chantrapanichkul, R. Craig Sineath, Michael Goodman, Jessica A. Alvarez, Vin Tangpricha

A R T I C L E   I N F O
Keywords:
- Transgender
- Gender affirming hormone therapy
- Body mass index

A B S T R A C T

Introduction: Many transgender people take hormone therapy to affirm their gender identity. One potential long-term consequence of gender affirming hormone therapy is increased body mass index (BMI), which may be associated with metabolic syndrome, cardiovascular disease and higher mortality. Only a few published studies explored changes in BMI in transgender people taking gender affirming hormone therapy (GAHT).

Objective: To examine the changes in BMI longitudinally in response to GAHT in transgender women and men.

Methods: We conducted a retrospective cohort study of transgender individuals who received GAHT from the endocrinology clinic between January 1, 2000 and September 6, 2018. Subjects who sought GAHT were included if they had two separate measurements of BMI and were excluded if they had a BMI greater than 35 kg/m² or were missing demographic data at entry. We used a linear mixed model to analyze the longitudinal change in BMI.

Results: There were a total of 237 subjects included in this cohort. Among subjects already on GAHT, transgender women were receiving GAHT longer than transgender men (6.59 ± 9.35 vs 3.67 ± 3.43 years, p-value = 0.04). Over the period of 7 years, there was a significant increase in BMI in transwomen who newly initiated GAHT (p-value 0.004). There were no changes in BMI in transgender men and women already on GAHT or in transgender men who newly initiated GAHT in the study.

Conclusion: We conclude that BMI significantly increases in transwomen but not in transmen after initiation of GAHT in a single center based in the United States. In transwomen and transmen, BMI appears to be stable following 3 to 6 years of GAHT. Future investigations should examine the causes for increased BMI in transgender women including type of GAHT, diet and lifestyle, and association with risk of metabolic syndrome and cardiovascular disease.

Introduction

Transgender persons receive gender affirming hormone therapy (GAHT) to align their physical characteristics with their affirmed gender identity and to improve quality of life [1]. The long-term risks of GAHT are low, but may include higher incidence of venous thromboembolism, cerebrovascular accidents (CVA) and cardiovascular disease (CVD) in transgender women and polycythemia, acne, and androgenic alopecia in transgender men [2,3]. Guidelines from the Endocrine Society and World Professional Association for Transgender Health exist to help mitigate the risk that potentially could occur from GAHT [4,5]. These guidelines recommend maintaining hormone values in the range expected for the affirmed gender and avoiding supraphysiological doses of GAHT. One area of concern for transgender people is increased body weight following hormone therapy [6,7]. Some studies demonstrate an increase in weight among both transgender women and transgender men [8]. Transfeminine hormone increases body fat and decreases lean body mass.
mass, whereas transmasculine hormone decreases body fat and increases lean body mass [9–11]. The increases in body weight, particularly fat mass, in transgender women may explain why GAHT is associated with increased CVA and CVD in transgender women but not in transgender men [12]. Increases in fat mass in transgender women as compared to transgender men may also predispose transgender women to increased risk of metabolic syndrome [13,14].

Body mass index (BMI) is highly correlated with adiposity, and is a commonly used clinical tool to assess risk for obesity and related metabolic diseases [15–19]. Several studies have documented that a high BMI is significantly associated, in both men and women, with metabolic syndrome [20,21], CVD [22–25] and mortality [26–29]. To date, only a few published studies have explored changes in BMI in transgender people taking GAHT. In transgender women, a significant increase in BMI was reported following GAHT for 12 months [30,31]. Conversely, transgender men were found to have a significantly higher BMI after 6 months [32,33] and after 54 months [31,34] following GAHT [35,36]. More longitudinal data on changes in BMI in response to GAHT, especially in the United States, are needed.

The purpose of this study is to examine the changes in BMI longitudinally, over seven years, in response to GAHT in both transgender women and men. We conducted a retrospective single center cohort study with a focus on changes in BMI. We hypothesized that GAHT would lead to changes in BMI in both transgender men and women. We further classified individuals in the cohort by whether they entered the cohort before or after the initiation of GAHT. We adjusted our primary outcome by age and duration of GAHT.

Methods

Cohort ascertainment and data collection

This was a retrospective study of transgender patients seen at the Emory Clinic between January 1, 2000 and September 6, 2018. The study was approved by the Emory Institutional Review Board.

The study participants were transgender patients who sought GAHT at our clinic, and received care from a single provider. The treatment protocol for gender affirming hormones followed the Endocrine Society clinical practice guidelines for treatment of gender-dysphoric/gender-incongruent persons [4,37]. Typically, transgender women received oral, transdermal or intramuscular estradiol along with spironolactone. Transgender men received intramuscular or transdermal testosterone. Subjects who were already taking GAHT and subjects who were evaluated before being prescribed GAHT were included in the study. Subjects were excluded if they were missing demographic data including BMI, had a single visit, or had a BMI higher than 35 kg/m² upon entry into the cohort. Subjects with BMI greater than 35 kg/m² were excluded because they were statistical outliers by the Z-scores statistical test. Subjects who had BMI values greater than 2 standard deviations from the mean at entry into the cohort were excluded from the study.

Data on each subject’s age, height and weight, and GAHT were extracted from the electronic medical records. BMI was the primary outcome of interest. BMI was calculated by dividing weight in pounds (lbs) by height in inches (in) squared and multiplying by a conversion factor of 703 to obtain the corresponding value in kg/m².

Statistical analysis

Statistical analyses of the association between duration of GAHT and changes in BMI were performed using linear mixed-effects models separately for four groups: 1) transgender women who initiated GAHT after enrollment in the study; 2) transgender women who enrolled in the study while already on GAHT; 3) transgender men who initiated GAHT after enrollment in the study; and 4) transgender men who enrolled in the study while already on GAHT. The exposure of interest was duration of GAHT measured in quarters (3-month intervals), and the primary outcome was BMI change over time. The random effects models were constructed to take into account that the temporal change in BMI may differ across subjects; however age at baseline was included in the model as a fixed effect to avoid possible co-linearity with time.

All four models had the following form:

\[ Y_{ij} = \beta_0 + \beta_1 \text{Age}_i + \beta_2 \text{Time}_i + \nu_{i0} + \nu_{ij} + \epsilon_{ij} \]

for i ∈ {1, ..., n}, and j ∈ {1, ..., m} where

- \( Y_{ij} \) is the response for jth measurement of ith patient.
- \( \beta_0 \) is the fixed intercept of the regression model.
- \( \beta_1 \) is the fixed slope for Age.
- \( \nu_{i0} \sim \mathcal{N}(0, \sigma_0^2) \) is the random intercept for ith subject.
- \( \nu_{ij} \sim \mathcal{N}(0, \sigma_1^2) \) is the random slope for ith subject.
- \( \epsilon_{ij} \sim \mathcal{N}(0, \sigma_e^2) \) is a Gaussian error term.

The results of the models were expressed as linear regression coefficients (β) and the corresponding 95% confidence intervals (CI). The main measure of association was β estimate for GAHT, which represents average change in BMI with each additional quarter (3-month interval) of treatment duration. In addition, statistical results of the fixed effects were fitted by restricted maximum likelihood (REML) and presented with Satterthwaite’s approximation method in the lmerTest R package.

To facilitate visualization of changes of BMI over time, we constructed boxplots of BMI distributions. This approach presents boxes showing median values, ranges and quartiles of BMI for each quarter. If the sample size for a given quarter was too small (n ≤ 2), the boxplot for that quarter was omitted from the plot.

Results

Cohort description

We identified 227 transgender individuals who were potentially eligible for inclusion in the study. Thirteen individuals were not included because of a missing BMI value at the first recorded visit. We also excluded 33 subjects who had initial BMI greater than 35 kg/m² and 36 subjects who had only a single visit during the period of study. The final analytic cohort consisted of 145 transgender individuals further classified into 4 groups: 59 transgender women and 46 transgender men who were not yet initiated but subsequently started on GAHT and 25 transgender women and 15 transgender men who were already receiving GAHT (Fig. 1).

The baseline demographic characteristics of the study cohort are presented in Table 1. Subjects who were already taking GAHT prior to entry in the cohort were significantly older than the subjects not already taking GAHT in both transgender women (43.91 ± 15.58 years old vs 32.75 ± 11.67 years old) and transgender men (40.40 ± 13.11 years old vs 27.36 ± 8.84 years old). Most of subjects in each group were Caucasian. For subjects who entered the cohort already on GAHT, the mean BMI in transgender women and men were similar upon entry in the cohort (Table 1). The mean height and weight of transgender women were significantly higher than that of transgender men, p-value < 0.001 and p-value = 0.02, respectively. For subjects who entered cohort before the initiation of GAHT, transgender men and women had similar baseline BMI values. Transgender women already on GAHT were receiving GAHT longer than transgender men already on GAHT (6.6 years vs 3.7 years, p-value = 0.04). In subjects who entered cohort already on hormone therapy, the mean BMI in transgender women and men were similar upon entry in the cohort compared to those who were naïve to GAHT.

Longitudinal BMI changes among transgender women

In transgender women who entered the cohort already on GAHT, there were no significant changes in BMI over the study period
Transgender women who entered the cohort before the initiation of GAHT and then subsequently began GAHT experienced increases in BMI over the study period of 7 years. The changes in BMI appeared to be especially more prominent in the lower quartiles of BMI (Fig. 2B). Among transgender women who enrolled in the study prior to starting GAHT, BMI increased on average 0.125 kg/m² (95% CI 0.04–0.21, p-value = 0.004) per each additional quarter of therapy duration. In the corresponding analyses for transgender women who joined the cohort already on GAHT, the BMI changes were in the same direction but less pronounced and not statistically significant (β = 0.08, 95% CI −0.004–0.16, p-value = 0.064) (Fig. 2). In transgender women initiating on GAHT, the linear mixed model showed a significant relationship between age and duration of GAHT (Table 2, Model 2).

(Fig. 2A). Transgender women who entered the cohort before the initiation of GAHT and then subsequently began GAHT experienced increases in BMI over the study period of 7 years. The changes in BMI appeared to be especially more prominent in the lower quartiles of BMI (Fig. 2B). Among transgender women who enrolled in the study prior to starting GAHT, BMI increased on average 0.125 kg/m² (95% CI 0.04–0.21, p-value = 0.004) per each additional quarter of therapy duration. In the corresponding analyses for transgender women who joined the cohort already on GAHT, the BMI changes were in the same direction but less pronounced and not statistically significant (β = 0.08, 95% CI −0.004–0.16, p-value = 0.064) (Fig. 2). In transgender women initiating on GAHT, the linear mixed model showed a significant relationship between age and duration of GAHT (Table 2, Model 2).

Table 1
Baseline characteristics of transgender women and transgender men who underwent gender affirming hormone therapy (GAHT).

|                        | Transgender women                                      | Transgender men                                      |
|------------------------|--------------------------------------------------------|------------------------------------------------------|
|                        | Already on GAHT (n = 46)                               | Hormone naive (n = 59)                               | Already on GAHT (n = 15) | Hormone naive (n = 25) |
| Age                    | 43.9 ± 15.6                                            | 32.8 ± 11.7**                                        | 40.4 ± 13.1              | 27.4 ± 8.8†           |
| Race (%)               |                                                        |                                                      |                         |                      |
| Caucasian              | 52.1%                                                  | 71.2%                                                | 66.7%                    | 68.0%                 |
| African American       | 23.9%                                                  | 8.5%                                                 | 6.7%                     | 12.0%                 |
| Asian                  | 4.4%                                                   | 1.7%                                                 | 6.7%                     | 0%                    |
| Multiple               | 0%                                                     | 1.7%                                                 | 6.7%                     | 4.0%                  |
| Unknown                | 19.6%                                                  | 16.9%                                                | 13.2%                    | 16.0%                 |
| BMI (kg/m²)            | 26.3 ± 4.7                                             | 24.7 ± 4.7                                           | 26.6 ± 4.2               | 24.4 ± 5.4            |
| Height (Inches)        | 69.7 ± 3.6                                             | 69.5 ± 2.4                                           | 64.6 ± 3.1†              | 65.4 ± 3.1†           |
| Weight (Pounds)        | 182.6 ± 41.8                                          | 169.1 ± 34.6                                         | 158.6 ± 30.5†            | 147.7 ± 34.5†         |
| Years on Hormone       | 6.6 ± 9.35                                             | 0                                                   | 3.7 ± 3.43†              | 0                     |

Values are given as mean ± SD of the 46 transgender women who entered the cohort already on GAHT compared with 59 transgender women who entered the cohort before the initiation of GAHT and the 15 transgender men who entered the cohort already on GAHT and 25 transgender men who entered the cohort before the initiation of GAHT are in both comparisons. BMI, body mass index *p < 0.05 (p-values represent significance from log-transformed variables when relevant). We also compare transgender women to transgender men who already on hormone and transgender women to transgender men who hormone naïve. †p < 0.05 (p-values represent significance from log-transformed variables when relevant).
Longitudinal changes in BMI among transgender men

Transgender men who entered the cohort on GAHT did not experience a change in BMI during the study period (Fig. 2C). Likewise, transgender men who entered the cohort prior to starting GAHT and subsequently began GAHT did not see changes in BMI over 7 years following the initiation of GAHT (P-value = 0.790). In the linear mixed-model, neither BMI and age were correlated in both groups. Also, there was no correlation between BMI and duration of hormone therapy in both groups (Table 2, Model 3 & 4).

Discussion

This retrospective cohort of transgender individuals undergoing GAHT over a period of 7 years demonstrated a significant increase of BMI in transgender women who entered the cohort before the initiation of GAHT and no changes in BMI among transgender women already on GAHT for an average of 6.6 years. There were no significant changes in BMI in transgender men regardless of the timing of enrolment relative to GAHT initiation. The increase in BMI among transgender women appeared to occur primarily in the first 24 months of therapy followed by a plateau around the third year of GAHT. This may explain why transgender women already on GAHT prior to entry in the cohort did not experience changes in BMI during the study period.
Table 2
Association of BMI in four cohorts of transgender men and women receiving gender affirming hormone therapy (GAHT) using linear mixed model.

| Model 1: Transgender women who entered the cohort after on GAHT for more than 6 months (N = 46) | Fixed Effects | Estimate | 95%CI | P-value |
|---|---|---|---|---|
| Intercept | 18.66 | [14.91, 22.41] | < 0.001 |
| Age (years) | 0.17 | [0.08, 0.25] | < 0.001 |
| GAHT duration (quarters) | 0.08 | [−0.004, 0.16] | 0.064 |

| Model 2: Transgender women who entered the cohort prior to starting GAHT (N = 59) | Fixed Effects | Estimate | 95%CI | P-value |
|---|---|---|---|---|
| Intercept | 20.85 | [16.24, 24.3] | < 0.001 |
| Age (years) | 0.15 | [0.05, 0.25] | 0.004 |
| GAHT duration (quarters) | 0.13 | [0.04, 0.21] | 0.004 |

| Model 3: Transgender men who entered the cohort after on GAHT for more than 6 months (N = 15) | Fixed Effects | Estimate | 95%CI | P-value |
|---|---|---|---|---|
| Intercept | 19.62 | [13.5, 25.8] | < 0.001 |
| Age (years) | 0.14 | [−0.03, 0.31] | 0.101 |
| GAHT duration (quarters) | −0.02 | [−1.28, 1.24] | 0.739 |

| Model 4: Transgender men who entered the cohort prior to starting GAHT (N = 25) | Fixed Effects | Estimate | 95%CI | P-value |
|---|---|---|---|---|
| Intercept | 19.62 | [14.2, 25.05] | < 0.001 |
| Age (years) | 0.16 | [−0.03, 0.34] | 0.093 |
| GAHT duration (quarters) | −0.02 | [−0.14, 0.11] | 0.790 |

P-value represent significance from log-transformed variables when relevant.

not demonstrate changes in this BMI during our study.

Reports on BMI among the transgender population have been mixed. Two prospective observational studies conducted in Europe reported that BMI increased in transgender women after 12 months of GAHT [30,38,39]. Another longitudinal cohort study in transgender girls in Europe also reported a significant increase in BMI from the start of GAHT from a mean age of 15 years up to the age of 22 years [40]. However, other studies have not reported increases in BMI over a similar period of time [8,10,41], although they have reported an increase in total body fat along with a significant decrease in lean body mass. The European Network for the Investigation of Gender Incongruence (ENIGI) study reported that the BMI at the initiation of GAHT appears to be a determinant of changes in body composition. A higher baseline BMI in transgender women was related to a smaller increase in body fat and larger decrease in lean body mass [42]. Four observational studies of transgender women in the US observed no change in BMI [10,43–45]. In transgender men, three studies show no change in BMI [44–46]; three studies showed an increase in BMI [10,43,47] and one study observed a decrease in BMI [48]. Results from these US-based studies are not directly comparable to ours because these studies were relatively small with cohort size of between 16 and 38 and short term had follow-up periods in the range of 6–35 months [10,43–48]. Our findings also differ from those published in Europe likely due to the differences in GAHT regimens. Our regimen for transwomen includes spironolactone whereas the main testosterone-lowering medication used in Europe is cyproterone. Cyproterone seems to have a stronger anti-androgenic effect than spironolactone which may lead to differences in body composition and adiposity.

In transgender men, there have been a few studies examining the long-term changes following GAHT on BMI. One previous observational study in Europe suggested a significant increase in BMI following 36 months of GAHT [49]. Additionally, one clinical trial of transgender men assigned participants to 3 different testosterone formulations and reported a significant increase in BMI after 54 months of treatment in all three study arms [34]. In contrast to these results, we found no changes in BMI after 7 years in both subjects who entered the cohort before initiation of GAHT and subjects who were already on GAHT. We hypothesize that testosterone may decrease body fat and increase lean body mass leading to an unchanged BMI. Other cohort studies examining transgender men on GAHT reported similar findings on BMI over the periods of 12 months and 24 months [35,50]. Therefore, it is possible that changes in body composition occurred in the transgender men in our cohort without detectable changes in BMI.

Higher BMI typically reflects increases in adiposity in most adults [51]. Elevated BMI is strongly associated with visceral adiposity, cardiometabolic disease and mortality in the general population [23,51–53]. For transgender women taking GAHT, a gain in fat, a decline in lean body mass, and an increase in insulin resistance have been reported, while the opposite effects are seen in transgender men [8,14,54]. These changes would predict that transgender women should be at higher risk for cardiovascular events compared to transgender men, which is in agreement with previous reports [9,55–59]. Moreover, one randomized controlled trial suggests that dose of GAHT may impact changes in BMI [6]. In order to decrease cardiovascular morbidity, particularly among transgender women, more attention should be paid to decreasing cardiovascular risk factors such as BMI and other factors such as hypertension, hyperlipidemia, and tobacco use [60]. Furthermore, longer term studies evaluating the impact of GAHT on BMI and other risk factors need to be conducted.

Some limitations of these data warrant consideration. It is important to acknowledge that BMI is a surrogate of adiposity; it does not provide indication of body composition or body fat distribution. Our study was not able to directly link GAHT to increased BMI because there may be other confounding factors such as diet, exercise, mental health status, lifestyle or behaviors that may affect or mediate this association. Another limitation of our study is that some subjects in the cohort were already on GAHT so we do not have their starting BMI prior to GAHT. As this was a retrospective chart review, we based our height measurements on clinic collected data. One potential source of error could be the measurement of height; although height for each patient was measured consistently at each visit using a stadiometer. Finally, we may not have a sufficiently long enough follow-up period or sample size to definitively say that BMI does not change following GAHT among transgender men.

We conclude that BMI significantly increases in transgender women but not in transgender men after initiation of GAHT in a single center based in the United States. In both transgender women and transgender men, BMI appears to be stable following 3 to 6 years of GAHT. Future investigations should focus on what factors may lead to increases in BMI including type of GAHT, changes in diet and lifestyle and what is the relationship between increased BMI and risk of metabolic syndrome and cardiovascular disease.

Funding
This study was funded in part by the Prince Mahidol Foundation, National Institutes of Health R21HD076387 from the Eunice Kennedy Shriver National Institute of Child Health, United States; Human Development, United States; The National Center for Advancing Translational Sciences of the National Institutes of Health, United States, under Award Number ULTR002378. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

CRediT authorship contribution statement
Pichatorn Suppakitjanusant: Conceptualization, Methodology, Writing - original draft, Writing - review & editing. Yuhan Ji: Formal analysis, Writing - original draft. Mary O. Stevenson: Data curation, Writing - original draft, Writing - review & editing. Panicha P. Suppakitjanusant, et al. Journal of Clinical & Translational Endocrinology 21 (2020) 100230
Chantapanichkul: B. Craig Sineath: Data curation, Writing - original draft, Writing - review & editing. Michael Goodman: Conceptualization, Methodology, Writing - original draft, Writing - review & editing, Resources, Supervision. Jessica A. Alvarez: Writing - original draft, Writing - review & editing. Vin Tangpricha: Conceptualization, Methodology, Writing - original draft, Writing - review & editing, Resources, Supervision.

References

[1] Safer JD, Tangpricha V. Care of transgender persons. New Engl J Med. 381(25):2019: 2451-60.
[2] Tangpricha V, den Heijer M. Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol 2017;5(4):291–306.
[3] Safer JD, Tangpricha V. Care of the transgender patient. Ann Intern Med 2019;171(10):775-6.
[4] Hembree WC, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2017;102(11):3869-903.
[5] WPATH Standards of Care for the health of transgender, gender nonconforming people 7th version; 2012.
[6] Fernandez JD, et al. Assessment of gender-affirming hormone therapy requirements. LGBT Heal 2019;6(3):101-6.
[7] Tjoen G, et al. Endocrinology of transgender medicine. Endocr Rev 2019;40(1):97-117.
[8] Klaver M, et al. Cross-sex hormone therapy in transgender persons affects total body weight, body fat and lean body mass: a meta-analysis. Andrologia 49(5); 2017.
[9] Gooren LJ, Wierckx K, Giljay EL. Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern. Eur J Endocrinol 2014;170(6):809-19.
[10] Deutsch MB, Bhakri V, Kubicek K. Effects of cross-sex hormone treatment on transgender women and men. Obest Gynecol 2015;125(3):605–10.
[11] Giljay EL, et al. Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration. Arterioscler Thromb Vasc Biol 1998;18(11):1716-22.
[12] Getzhan D, et al. Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study. Ann Intern Med 2018;169(4):205-13.
[13] Shadid S, et al. Effects of gender-affirming hormone therapy on insulin sensitivity and incretin responses in transgender people. Diab Care 2020;43(2):411-7.
[14] Spaccio C, et al. Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: a systematic review. World J Diab 2020;11(3):66-77.
[15] Steinerberger J, et al. Comparison of body fatness measurements by BMI and skinfolds vs dual energy X-ray absorptiometry and their relation to cardiovascular risk factors in adolescents. Int J Obes (Lond) 2005;29(11):1346-52.
[16] Lawlor DA, et al. Body mass index and skinfold thicknesses to cardiovascular disease risk factors in children: the Bogalusa Heart Study. Am J Clin Nutr 2009;89(1):213-9.
[17] Freedman DS, et al. Relation of body mass index and skinfold thicknesses to cardiovascular disease risk factors in young adults. Circulation 1993;87(5):986-77.
[18] Mynykà A, Chang VW. Weight change, initial BMI, and mortality among middle- and older-aged adults. Epidemiology 2009;20(6):840-8.
[19] Kittahara CM, et al. Association between class III obesity (BMI of 40-59 kg/m2) and mortality: a pooled analysis of 20 prospective studies. PLoS Med 2014;11(7):e1001763.
[20] Stenholm S, et al. Body mass index as a predictor of healthy and disease-free life expectancy between ages 50 and 75%: a multistudy cohort. Int J Obes (Lond)

2017;41(5):769-75.
[21] Manson JE, et al. Body weight and mortality among women. N Engl J Med 1995;333(11):677-85.
[22] Mueller A, et al. Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist. Exp Clin Endocrinol Diabetes 2011;119(2):95–100.
[23] Ott J, et al. Cross-sex hormone therapy alters the serum lipid profile: a retrospective cohort study in 169 transsexuals. J Sex Med 2011;8(8):2361–9.
[24] Berra M, et al. Testosterone decreases adiponectin levels in female to male transsexuals. Asian J Androl 2006;8(6):725-9.
[25] Sequeira GM, et al. Early effects of testosterone initiation on body mass index in transmasculine adolescents. J Adolesc Heal 2019;65(5):818-20.
[26] Pelusi C, et al. Effects of three different testosterone formulations in female-to-male transsexual persons. J Sex Med 2014;11(12):3002-11.
[27] Mueller A, et al. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in male-to-female transsexuals. J Sex Med 2010;7(9):3190-8.
[28] Cupisti S, et al. The impact of testosterone administration to female-to-male transsexuals on insulin resistance and lipid parameters compared with women with polycystic ovary syndrome. Fertil Steril 2010;94(7):2347-51.
[29] Hembree WC, et al. Endocrine treatment of transgender persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2009;94(9):3152-54.
[30] Fisher AD, et al. Cross-sex hormone treatment and psychological changes in transsexual persons: two-year follow-up data. J Clin Endocrinol Metab 2016;101(11):4260–9.
[31] van Velzen DM, et al. Cardiometabolic effects of testosterone in transmen and estrogen plus cyproterone acetate in transwomen. J Clin Endocrinol Metab 2019;104(9):3287-95.
[32] Klaver M, et al. Hormonal treatment and cardiovascular risk profile in transgender adolescents. Pediatrics 2020;145(3):e20190741.
[33] Fighera TM, et al. Impact of cross-sex hormone therapy on bone mineral density and body composition in transgender women. Clin Endocrinol (Oxf) 2018;88(6):856-62.
[34] Klaver M, et al. Changes in regional body fat, lean body mass and body shape in trans persons using cross-sex hormone therapy: results from a multicenter prospective study. Eur J Endocrinol 2018;178(2):163–71.
[35] Fernandez JD, Tannock LB. Metabolic effects of hormone therapy in transgender patients. Endocr Pract 2016;22(4):383-8.
[36] Olson-Kennedy JL, et al. Physiologic response to gender-affirming hormones among transgender youth. J Adolesc Health 2018;62(4):397–401.
[37] Jamin J, et al. Cross-sex hormones and metabolic parameters in adolescents with gender dysphoria. Pediatrics 2017;139(5).
[38] Chandra P, et al. Alterations in lipids and adipocyte hormones in female-to-male transsexuals. Int J Endocrinol 2010;2010.
[39] Olson J, et al. Subcutaneous testosterone: an effective delivery mechanism for masculinizing young transgender men. LGBT Health 2014;1(3):165–7.
[40] Chan RJ, et al. Exogenous testosterone does not induce or exacerbate the metabolic features associated with PCOS among transgender men. Endocr Pract 2018;24(6):565-72.
[41] Jacobiet JW, Gooren LJ, Schulte HM. Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender persons: a phase 3 trial. Ann Intern Med 2018;168(5):557-65.
[42] Van Caeckenbergh E, et al. Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study (ENIGC). Eur J Endocrinol 2015;172(2):163–71.
[43] Adab P, Fullam M, Whincup PH. Is BMI the best measure of obesity? BMJ 2018;360:k1274.
[44] Nazare JA, et al. Usefulness of measuring both body mass index and waist circumference for the estimation of visceral adiposity and related cardiometabolic risk. (from the INSPIRE ME IAA study). Am J Cardiol 2015;115(3):507-15.
[45] Ortega FB, et al. Body mass index, the most widely used but also widely criticized index: would a criterion standard measure of total body fat be a better predictor of cardiovascular disease mortality? Mayo Clin Proc 2016;91(4):443-55.
[46] Nokoff NJ, et al. Body composition and markers of cardiometabolic health in transgender youth compared with cisgender youth. J Clin Endocrinol Metab 2020;105(3).
[47] Wierckx K, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med 2008;5(9):2641-51.
[48] Asscheman H, Gooren LG. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2011;164:635–42.
[49] Wils A, et al. Metabolic and functional changes in transgender individuals following cross-sex hormone treatment: design and methods of the GENDER Dysphoria Treatment in Sweden (GETS) study. Contemp Clin Trials Commun 2018;10:148–53.
[50] Quinn VP, et al. Cohort profile: Study of Transition, Outcomes and Gender (STO) to assess health status of transgender people. BMJ Open 2017;7(12):e018121.
[51] Streed Jr CG, et al. Cardiometabolic disease among transgender adults requiring hormone therapy: a narrative review. Ann Intern Med 2017;167(4):256-67.
[52] Defreyn J, et al. Effects of gender-affirming hormones on lipid, metabolic, and cardiac surrogate blood markers in transgender persons. Clin Chem 2019;65(5):119-34.